Evidence map›Paper›PMID 24920969›Full record

ArticleThe World Allergy Organization journal2014

International consensus on (ICON) anaphylaxis.

F Estelle R Simons, Ledit Rf Ardusso, M Beatrice Bilò, Victoria Cardona, Motohiro Ebisawa, Yehia M El-Gamal, Phil Lieberman, Richard F Lockey, Antonella Muraro, Graham Roberts and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04755881 (SHARED), which is not on this map. Cited by 125 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 1 pooled it
27.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04755881 terminatednot on this mapstarted 2019, after this paper: background citation

SHARED (Saguenay Hospitals Anaphylaxis Rule for Early Discharge) - Phase 2 : a Prospective Theoretical Validation

Typeobservational_patient_registrySponsorUniversité de SherbrookeRan2019 to 2023Enrolled191ConditionsAnaphylaxis, Biphasic Anaphylactic Reaction, Rebound Anaphylactic ReactionArmsOccurence of biphasic reaction following anaphylaxis
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 1 synthesis or guideline pooled it, 475 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis.The Journal of allergy and clinical immunology · 2017
    Trial
  5. Triggers, clinical spectra and outcomes of pediatric anaphylaxis in a tertiary center: impact of comorbidities and cofactors on severity.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Anaphylaxis and pregnancy: Epidemiology, elicitors, and recurrences.The World Allergy Organization journal · 2025
    Article
  10. Article
  11. Article
  12. Progress and Challenges in the Treatment of Fabry Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Who is at-risk for severe anaphylaxis in France?The World Allergy Organization journal · 2024
    Article
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 11 countries.

F Estelle R SimonsDepartment of Pediatrics & Child Health and Department of Immunology, Faculty of Medicine, University of Manitoba, Room FE125, 820 Sherbrook Street, Winnipeg, Manitoba, Canada, R3A 1R9.
Ledit Rf ArdussoCátedra Neumonología, Alergia e Inmunología, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina.
M Beatrice BilòAllergy Unit, Department of Internal Medicine, University Hospital, Ancona, Italy.
Victoria CardonaAllergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Motohiro EbisawaDepartment of Allergy, National Hospital Organization, Sagamihara National Hospital, Clinical Research Center for Allergy & Rheumatology, Kanagawa, Japan.
Yehia M El-GamalPediatric Allergy and Immunology Unit, Ain Shams University, Cairo, Egypt.
Phil LiebermanAllergy and Asthma Associates, Germantown, TN, USA.
Richard F LockeyUniversity of South Florida Morsani College of Medicine, Tampa, FL, USA.
Antonella MuraroDepartment of Women and Child Health, Food Allergy Referral Centre, University of Padua, Padua, Italy.
Graham RobertsUniversity of Southampton Faculty of Medicine, Southampton, United Kingdom, David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Isle of Wight, United Kingdom.
Mario Sanchez-BorgesCentro Medico Docente La Trinidad, Caracas, Clinica El Avila, Caracas, Venezuela.
Aziz SheikhCenter for Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom and Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.
Lynette P ShekDepartment of Pediatrics, National University of Singapore, Singapore.
Dana V WallaceNova Southeastern University, Fort Lauderdale, FL, USA.
Margitta WormAllergie-Centrum-Charité, Klinik fur Dermatologie und Allergologie, Charité, Universitatsmedizin, Berlin, Germany.
Ain Shams University · EGCentro Médico Docente La Trinidad · VECharité - Universitätsmedizin Berlin · DENational Sagamihara Hospital · JPNational University of Rosario · ARNational University of Singapore · SGNova Southeastern University · USOspedali Riuniti di Ancona · ITSt Mary's Hospital · GBUniversity of Manitoba · CAUniversity of Padua · ITUniversity of South Florida · USVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

iconAnaphylaxis provides a unique perspective on the principal evidence-based anaphylaxis guidelines developed and published independently from 2010 through 2014 by four allergy/immunology organizations. These guidelines concur with regard to the clinical features that indicate a likely diagnosis of anaphylaxis -- a life-threatening generalized or systemic allergic or hypersensitivity reaction. They also concur about prompt initial treatment with intramuscular injection of epinephrine (adrenaline) in the mid-outer thigh, positioning the patient supine (semi-reclining if dyspneic or vomiting), calling for help, and when indicated, providing supplemental oxygen, intravenous fluid resuscitation and cardiopulmonary resuscitation, along with concomitant monitoring of vital signs and oxygenation. Additionally, they concur that H1-antihistamines, H2-antihistamines, and glucocorticoids are not initial medications of choice. For self-management of patients at risk of anaphylaxis in community settings, they recommend carrying epinephrine auto-injectors and personalized emergency action plans, as well as follow-up with a physician (ideally an allergy/immunology specialist) to help prevent anaphylaxis recurrences. ICON: Anaphylaxis describes unmet needs in anaphylaxis, noting that although epinephrine in 1 mg/mL ampules is available worldwide, other essentials, including supplemental oxygen, intravenous fluid resuscitation, and epinephrine auto-injectors are not universally available. ICON: Anaphylaxis proposes a comprehensive international research agenda that calls for additional prospective studies of anaphylaxis epidemiology, patient risk factors and co-factors, triggers, clinical criteria for diagnosis, randomized controlled trials of therapeutic interventions, and measures to prevent anaphylaxis recurrences. It also calls for facilitation of global collaborations in anaphylaxis research. IN ADDITION TO CONFIRMING THE ALIGNMENT OF MAJOR ANAPHYLAXIS GUIDELINES, ICON: Anaphylaxis adds value by including summary tables and citing 130 key references. It is published as an information resource about anaphylaxis for worldwide use by healthcare professionals, academics, policy-makers, patients, caregivers, and the public.

Indexed as

Acute systemic allergic reactionAnaphylaxisDrug allergyEpinephrine (adrenaline)Exercise-induced anaphylaxisFood allergyGlucocorticoidsH1-antihistaminesH2-antihistaminesIdiopathic anaphylaxisVenom allergy

Identifiers

PMID24920969
PMCPMC4038846
OpenAlexW2097022788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.